Advanced lipid panel (ApoB + Lp(a))
Diagnostics · Cardiovascular risk
Tier S
What this is
Peter Attia / Allan Sniderman have driven ApoB adoption into mainstream biohacker/longevity practice. Target ApoB <60 mg/dL for aggressive primary prevention, <80 mg/dL for standard. Lp(a) >50 mg/dL (or >125 nmol/L) is an independent risk factor treatable with PCSK9i, niacin, or emerging Lp(a)-specific agents (pelacarsen, olpasiran in trials).
Mechanism
ApoB = count of atherogenic particles (one per LDL, IDL, VLDL, Lp(a)) — more accurate than LDL-C for risk, especially in insulin-resistant phenotypes (discordant LDL-C vs ApoB); Lp(a) = genetically determined additional risk factor, measured once in lifetime
Dose & route
ApoB annually or with lipid changes; Lp(a) once (genetically determined, stable)
Citations
- https://pubmed.ncbi.nlm.nih.gov/31517778/
- https://pubmed.ncbi.nlm.nih.gov/30922368/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8063588/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.